Price T Rowe Associates Inc Kodiak Sciences Inc. Transaction History

Price T Rowe Associates Inc

  • $869 Billion
  • Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 11,446 shares of KOD stock, worth $73,597. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,446
Holding current value
$73,597
% of portfolio
0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$2.2 - $3.25 $25,181 - $37,199
11,446 New
11,446 $30,000
Q2 2023

Aug 14, 2023
BUY
$4.3 - $9.48 $2.13 Million - $4.69 Million
494,463 New
494,463 $3.41 Million
Q4 2022

Feb 14, 2023
SELL
$6.52 - $8.05 $1.79 Million - $2.21 Million
-273,966 Reduced 36.73%
472,013 $3.38 Million
Q3 2022

Nov 14, 2022
BUY
$7.57 - $12.5 $677,976 - $1.12 Million
89,561 Added 13.64%
745,979 $5.77 Million
Q2 2022

Aug 15, 2022
SELL
$5.04 - $9.48 $139,759 - $262,880
-27,730 Reduced 4.05%
656,418 $5.02 Million
Q1 2022

May 16, 2022
SELL
$7.09 - $89.45 $52.7 Million - $665 Million
-7,432,314 Reduced 91.57%
684,148 $5.28 Million
Q4 2021

Feb 14, 2022
BUY
$80.85 - $128.49 $4.87 Million - $7.74 Million
60,232 Added 0.75%
8,116,462 $688 Million
Q3 2021

Nov 15, 2021
BUY
$81.97 - $106.94 $52.7 Million - $68.8 Million
643,080 Added 8.67%
8,056,230 $773 Million
Q2 2021

Aug 16, 2021
BUY
$77.2 - $126.54 $42.6 Million - $69.8 Million
551,429 Added 8.04%
7,413,150 $689 Million
Q1 2021

May 17, 2021
BUY
$110.45 - $164.47 $75.7 Million - $113 Million
685,510 Added 11.1%
6,861,721 $778 Million
Q4 2020

Feb 16, 2021
BUY
$60.78 - $154.03 $375 Million - $951 Million
6,176,211 New
6,176,211 $907 Million

Others Institutions Holding KOD

# of Institutions
98
Shares Held
39M
Call Options Held
6.5K
Put Options Held
5.8K
View Full List

About Kodiak Sciences Inc.

KOD Quotes by TradingView
  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $335M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email